Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802).
Sign Up to like & getrecommendations! Published in 2020 at "Clinical colorectal cancer"
DOI: 10.1016/j.clcc.2020.01.003
Abstract: INTRODUCTION Biweekly schedule of XELOX-2 (capecitabine plus oxaliplatin) showed interesting results in first-line therapy of patients with metastatic colorectal cancer (mCRC). Bevacizumab plus FOLFOX-4 (oxaliplatin, folinic acid, and infusional 5-fluorouracil) is among standard first-line treatment… read more here.
Keywords: xelox; bevacizumab; first line; either folfox ... See more keywords